Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Background: This study aimed to evaluate the efficacy, side-effects and resistance mechanisms of first-line afatinib in a real-world setting. Methods: This is a multicenter observational study of first-line afatinib in Malaysian patients with epidermal growth factor receptor (EGFR)-mutant advance...
Saved in:
Main Authors: | Chai, Chee Shee, Ho, Gwo Fuang, Adlinda, Alip, Mohd Ibrahim, Abd Wahid, Matin Mellor, Abdullah, Foo, Yoke Ching, How, Soon Hin, Adel, Zaatar, Lam, Kai Seng, Leong, Kin-Wah, Low, JohnbSeng Hooi, Mastura, Md Yusof, Lee, Erica Chai Yong, Toh, Yok Yong, Liam, Chong Kin |
---|---|
Format: | Article |
Language: | English |
Published: |
Springer Nature
2019
|
Subjects: | |
Online Access: | http://ir.unimas.my/id/eprint/26798/1/Chai%2C%20Chee%20Shee.pdf http://ir.unimas.my/id/eprint/26798/ https://bmccancer.biomedcentral.com/articles/10.1186/s12885-019-6107-1 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
by: Ho, Gwo Fuang, et al.
Published: (2019) -
Real-world multicentre experience of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer
by: Liam, Chong Kin, et al.
Published: (2019) -
Afatinib as first-line treatment in Asian patients with EGFR mutation-positive NSCLC: A narrative review of real-world evidence
by: Lu, Shun, et al.
Published: (2021) -
Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
by: Chai, Chee Shee, et al.
Published: (2019) -
P3. 13-15 First-Line Afatinib Dose Initiation and Adjustment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
by: Chai, Chee Shee, et al.
Published: (2018)